Management of erythropoietic protoporphyria with cholestatic liver disease: A case report

Mol Genet Metab Rep. 2023 Oct 31:37:101018. doi: 10.1016/j.ymgmr.2023.101018. eCollection 2023 Dec.

Abstract

Erythropoietic protoporphyria (EPP) is a rare metabolic disease of the heme biosynthetic pathway where an enzymatic dysfunction results in protoporphyrin IX (PPIX) accumulation in erythroid cells. The porphyrins are photo-reactive and are responsible for severe photosensitivity in patients, thus drastically decreasing their quality of life. The liver eliminates PPIX and as such, the main and rare complication of EPP is progressive cholestatic liver disease, which can lead to liver failure. The management of this complication is challenging, as it often requires a combination of approaches to promote PPIX elimination and suppress the patient's erythropoiesis. Here we described a 3-year follow-up of an EPP patient, with three episodes of liver involvement, aggravated by the coexistence of a factor VII deficiency. It covers all the different types of intervention available for the management of liver disease, right through to successful allogeneic hematopoietic stem cell transplantation.

Keywords: Cholestasis; Erythropoietic; Hematopoietic stem cell transplantation; Intrahepatic; Iron; Protoporphyria; Protoporphyrin IX.

Publication types

  • Case Reports